伴有2型糖尿病和代谢综合症高血压患者治疗的拉丁美洲共识.pdfVIP

Guidelines Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome Patricio Lo′ pez-Jaramilloa, Ramiro A. Sa′nchezb, Margarita Diazc, Leonardo Cobosd, Alfonso Brycee, Jose Z. Parra Carrillof, Fernando Lizcanog, Fernando Lanash, Isaac Sinayi, Iva′n D. Sierraj, Ernesto Pen? aherrerak, Mario Benderskyl, Helena Schmidm, Rodrigo Boteron, Manuel Urinao, Joffre Larap, Milton C. Fossq, Gustavo Ma′rquezr, Stephen Harraps, Agust?′n J. Ram?′rezb, Alberto Zanchettit, on behalf of the Latin America Expert Group The present document has been prepared by a group of end-stage renal disease; FDAU.S., US Food and Drug experts, members of cardiology, endocrinology and Administration; GFR, glomerular filtration rate; Hb A1c, diabetes societies of Latin American countries, to serve as glycosylated haemoglobin; HIC, high-income countries; a guide to physicians taking care of patients with diabetes, HOPE, Heart Outcomes Prevention Evaluation; HOT, hypertension and comorbidities or complications of both Hypertension Optimal Treatment Study; IDF, International conditions. Although the concept of ‘metabolic syndrome’ Diabetes Federation; IFG, impaired fasting glucose; IGTT, is currently disputed, the higher prevalence in Latin impaired glucose tolerance test; LIC, low-income countries; America of that cluster of metabolic alterations has MDRD, Modification of Diet in Renal Disease; OGTT, oral suggested that ‘metabolic syndrome’ is a useful glucose tolerance test; ONTARGET, Ongoing Telmisartan nosographic entity in the context of Latin American Alone and in Combination with Ramipril Global Endpoint medicine. Therefore, in the present document, particular Trial; PAHO, Pan American Health Organization; PURE, attention is paid to this syndrome in order to alert Prospective